Daniel James Ford
25Patents
2h-index
35Co-inventors
53Inventor score
Filing activity: Feb 7, 2011 → Apr 29, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10959398B1 | Experimental animal behavioral research methods and apparatuses | Electricity | 6 | Active |
| US8423517B2 | System and method for determining the age of objects in the presence of unreliable clocks | Physics | 4 | Active |
| US9096614B2 | Therapeutically active thiazolo-pyrimidine derivatives | Chemistry; Metallurgy | 1 | Active |
| US10596198B1 | Devices for selectively releasing volatile compounds | Human Necessities | 1 | Active |
| US11020396B2 | Pyrimidinone derivatives as Cdc7 inhibitors | Chemistry; Metallurgy | 1 | Active |
| US9700257B1 | Method of measuring gut transit time in animals | Physics | 1 | Active |
| US11033494B1 | Apparatuses containing an emulsion and methods of manufacture | Performing Operations; Transporting | 1 | Active |
| US9227984B2 | Therapeutically active fused pyrimidine derivatives | Chemistry; Metallurgy | 1 | Active |
| US9382263B2 | Therapeutically active oxazoline derivatives | Chemistry; Metallurgy | 0 | Active |
| US10506986B2 | Method of predicting severity of multiple sclerosis | Human Necessities | 0 | Active |
| US10420503B2 | Method of measuring efficacy of treatment for multiple sclerosis | Human Necessities | 0 | Active |
| US10087180B2 | Pyrazolo-pyridine derivatives as kinase inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
| US11109801B2 | Method of measuring efficacy of treatment for an autoimmune disease in vivarium animals | Human Necessities | 0 | Active |
| US9126979B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | Human Necessities | 0 | Active |
| US10789432B2 | Tracklets | Physics | 0 | Active |
| USRE48622E1 | Therapeutically active pyrazolo-pyrimidine derivatives | General | 0 | Active |
| US10188321B1 | Method of measuring animal health using motion vector analysis | Physics | 0 | Active |
| US10275686B2 | Method of reading arbitrary symbols | Physics | 0 | Active |
| US9969748B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
| US10568567B1 | Method of drug approval using motion vector analysis | Physics | 0 | Active |
| US10244979B2 | Method of early detection of multiple sclerosis | Human Necessities | 0 | Active |
| US10176397B2 | Method of reading degraded symbols | Physics | 0 | Active |
| US9029392B2 | Quinoline derivatives as kinase inhibitors | Human Necessities | 0 | Active |
| US11766434B2 | Pyrimidinone derivatives as CDC7 inhibitors | Chemistry; Metallurgy | 0 | Active |
| US9714248B2 | Therapeutically active pyrazolo-pyrimidine derivatives | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.